[Study on etoposide therapy of relapsing prostatic cancer patients]

Eight patients with hormone resistant prostate cancer were treated with 30 mg/m2 etoposide every two or three weeks. A response rate of 37.5% in clinical status was noted. Slight toxicity was seen temporarily. We think this etoposide therapy is a useful regimen for advanced or relapsing carcinoma of the prostate.